Lexeo Therapeutics Files 8-K

Ticker: LXEO · Form: 8-K · Filed: Oct 9, 2024 · CIK: 1907108

Lexeo Therapeutics, Inc. 8-K Filing Summary
FieldDetail
CompanyLexeo Therapeutics, Inc. (LXEO)
Form Type8-K
Filed DateOct 9, 2024
Risk Levellow
Pages3
Reading Time3 min
Key Dollar Amounts$0.0001
Sentimentneutral

Sentiment: neutral

Topics: sec-filing, 8-k

Related Tickers: LXEO

TL;DR

Lexeo filed an 8-K, check for updates.

AI Summary

Lexeo Therapeutics, Inc. filed an 8-K on October 9, 2024, reporting other events and financial statements. The filing does not disclose specific new events or financial figures but serves as a routine update.

Why It Matters

This 8-K filing indicates Lexeo Therapeutics is providing updates to the SEC, which could include material information relevant to investors.

Risk Assessment

Risk Level: low — The filing is a routine disclosure and does not contain specific negative or positive news that would immediately impact risk.

Key Players & Entities

  • Lexeo Therapeutics, Inc. (company) — Registrant
  • October 09, 2024 (date) — Date of earliest event reported
  • 345 Park Avenue South, Floor 6 (location) — Principal Executive Offices
  • New York, New York (location) — Principal Executive Offices
  • 10010 (location) — Principal Executive Offices Zip Code

FAQ

What is the primary purpose of this 8-K filing for Lexeo Therapeutics, Inc.?

The primary purpose of this 8-K filing is to report 'Other Events' and 'Financial Statements and Exhibits' as of October 9, 2024.

When was the earliest event reported in this filing?

The earliest event reported in this filing was on October 9, 2024.

What is Lexeo Therapeutics, Inc.'s principal executive office address?

Lexeo Therapeutics, Inc.'s principal executive office is located at 345 Park Avenue South, Floor 6, New York, New York, 10010.

What is Lexeo Therapeutics, Inc.'s telephone number?

Lexeo Therapeutics, Inc.'s telephone number is (212) 547-9879.

Under which section of the Securities Exchange Act is this report filed?

This report is filed pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.

Filing Stats: 766 words · 3 min read · ~3 pages · Grade level 13.7 · Accepted 2024-10-09 16:30:26

Key Financial Figures

  • $0.0001 — nge on which registered Common Stock, $0.0001 par value per share LXEO Nasdaq Glo

Filing Documents

01 Other Events

Item 8.01 Other Events. On October 9, 2024, Lexeo Therapeutics, Inc. (the " Company ") posted on its website an updated corporate presentation (the " Corporate Presentation "), noting the Company expects to share Cohort 1 data from LX2020 for the treatment of PKP2-ACM in the late first quarter or the early second quarter of 2025 and that the Company plans to present data from LX1001 for the treatment of APOE4-associated Alzheimer's disease at the Clinical Trials on Alzheimer's Disease conference in October 2024. The Corporate Presentation will be used from time to time in meetings with investors and analysts. A copy of the Corporate Presentation is attached hereto as Exhibit 99.1 and is incorporated by reference herein. Cautionary Note Regarding Forward-Looking Statements This report contains certain forward-looking statements regarding the business of the Company that are not a description of historical facts within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements regarding the Company's expected plans with respect to clinical trials of the Company's gene therapy candidates and the timing for announcement of data from such trials. Actual results could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, expectations regarding the initiation, progress, and expected results of the Company's preclinical studies, clinical trials and research and development programs, the unpredictable relationship between preclinical study results and clinical study results, delays in submission of regulatory filings or failure to receive regulatory approval and liquidity and capital resources. Additional risks and uncertainties that could cause actual results to differ materially from those contemplated by the forward-looking statements are included in the Company's Annual Report on Form 10-K for the fiscal ye

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit Number Description 99.1 Corporate Presentation, dated October 9, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Lexeo Therapeutics, Inc. Date: October 9, 2024 By: /s/ R. Nolan Townsend R. Nolan Townsend, Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.